Abstract
Interdisciplinary multimodal pain therapy (IMPT) is a biopsychosocial treatment approach for patients with chronic pain that comprises at least psychological and physiotherapeutic interventions. Core outcome sets (COSs) are currently developed in different medical fields to standardize and improve the selection of outcome domains, and measurement instruments in clinical trials, to make trial results meaningful, to pool trial results, and to allow indirect comparison between interventions. The objective of this study was to develop a COS of patient-relevant outcome domains for chronic pain in IMPT clinical trials. An international, multiprofessional panel (patient representatives [n = 5], physicians specialized in pain medicine [n = 5], physiotherapists [n = 5], clinical psychologists [n = 5], and methodological researchers [n = 5]) was recruited for a 3-stage consensus study, which consisted of a mixed-method approach comprising an exploratory systematic review, a preparing online survey to identify important outcome domains, a face-to-face consensus meeting to agree on COS domains, and a second online survey (Delphi) establishing agreement on definitions for the domains included. The panel agreed on the following 8 domains to be included into the COS for IMPT: pain intensity, pain frequency, physical activity, emotional wellbeing, satisfaction with social roles and activities, productivity (paid and unpaid, at home and at work, inclusive presentism and absenteeism), health-related quality of life, and patient's perception of treatment goal achievement. The complexity of chronic pain in a biopsychosocial context is reflected in the current recommendation and includes physical, mental, and social outcomes. In a subsequent step, measurement instruments will be identified via systematic reviews.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Pain |
| Jahrgang | 159 |
| Ausgabenummer | 4 |
| Seiten (von - bis) | 673-683 |
| Seitenumfang | 11 |
| ISSN | 0304-3959 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.04.2018 |
Fördermittel
J. A. Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, and the American College of Rheumatology. J. A. Singh serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc, a 501 (c) (3) entity. J. A. Singh is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arm’s length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J. A. Singh is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. C. Apfelbacher reports personal fees and nonfinancial support from Cogitando Healthcare, outside the submitted work. J. Schmitt reports grants from ALK, Novartis, Pfizer, Sanofi, outside the submitted work. E. Neugebauer reports personal fees from Gruenenthal, personal fees from AstraZeneca, outside the submitted work. U. Kaiser reports grants from BMBF during the conduct of the study. The remaining authors have no conflict of interest to declare. The study has been funded by German Ministry of Education and Research (BMBF 01GY1326).
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: The VAPAIN consensus statement on core outcome domains“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver